The Computational Biology Support Component (Leader, Thomas Kepler) will be organized into two teams: one team at Duke under Thomas Kepler, and the other at Los Alamos led by Bette Korber and Alan Perelson. Independently and jointly, they will work to surmount the two roadblocks: HlV-1 diversity and the inability to induce broad neutralizing antibodies (BnAbs) to HIV-1 envelope. Both sites will be involved in and collaborate on statistical analyses and immunogen design, but each will have its own primary focus. The Duke team will focus on the analysis and modeling of affinity maturation toward protective antibody phenotypes, including the inference of clonal histories back to the unmutated common ancestor and integrated analysis of structural, phenotypic, and genetic antibody data. The Los Alamos team will focus on polyvalent and mosaic immunogen design to overcome HIV diversity and assist in modeling affinity maturation and antibody repertoire. Together, the teams will statistically evaluate all results obtained from testing of the various designs as well as perform co-evolutionary analyses of BnAbs and transmitted/founder viral sequences together with the Viral Biology SRSC. Both teams will contribute to immunogen design and the development of different approaches.
Specific Aims Aim 1. Statistical analysis of HIV broadly neutralizing antibodies (BnAb) and vaccine-induced antibody and virus evolution.
Aim 2. Computational design of vaccine antigens for the induction and maturation of protective antibody responses.
The development of a vaccine against HIV infection remains a problem of great public concern. Researchers have learned a great deal recently about how the immune system and HIV-1 interact;sophisticated new approaches to vaccine design based on these findings are being tested. These methods call for correspondingly sophisticated computational methods, to be provided by the computational biology group.
|Pardi, Norbert; Hogan, Michael J; Naradikian, Martin S et al. (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215:1571-1588|
|Eudailey, Joshua A; Dennis, Maria L; Parker, Morgan E et al. (2018) Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. mSphere 3:|
|Kelsoe, Garnett; Haynes, Barton F (2018) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol 10:|
|Wagh, Kshitij; Kreider, Edward F; Li, Yingying et al. (2018) Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Rep 25:893-908.e7|
|Fu, Qingshan; Shaik, Md Munan; Cai, Yongfei et al. (2018) Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 115:E8892-E8899|
|Fera, Daniela; Lee, Matthew S; Wiehe, Kevin et al. (2018) HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. Nat Commun 9:1111|
|McMichael, Andrew J (2018) Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8+ T-Cell Vaccine Prevent Persistent HIV Infection? Cold Spring Harb Perspect Biol 10:|
|Williams, Wilton B; Han, Qifeng; Haynes, Barton F (2018) Cross-reactivity of HIV vaccine responses and the microbiome. Curr Opin HIV AIDS 13:9-14|
|Bonsignori, Mattia; Scott, Eric; Wiehe, Kevin et al. (2018) Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity 49:1162-1174.e8|
|Blasi, Maria; Negri, Donatella; LaBranche, Celia et al. (2018) IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Commun Biol 1:134|
Showing the most recent 10 out of 261 publications